Management of Nodular Lymphocyte-Predominant Hodgkin Lymphoma


In this video reviews the management of nodular lymphocyte-predominant Hodgkin lymphoma.

In this video, Dennis A. Eichenauer, MD, of the University of Cologne, Germany, reviews the management of nodular lymphocyte-predominant Hodgkin lymphoma.

Eichenauer gave a presentation on this topic, “Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Unique Disease Deserving Unique Management,” during an education session at the 2017 American Society of Hematology (ASH) Annual Meeting and Exposition, held December 9–12 in Atlanta.


Related Videos
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.
Considering notable adverse effects associated with treatment may be critical when selecting therapy options for those with CML.
Adverse effects associated with oral azacitidine in low- or intermediate-risk MDS are typically transient, according to Mikkael A. Sekeres, MD, MS.
Ongoing genomic profiling analyses in the ASC4FIRST trial may further determine which patients with CML may benefit from treatment with asciminib.
Naveen Pemmaraju, MD, with the Oncology Brothers
Related Content